Back to Investors
PI

Perivoli Innovations

Venture Capital

Perivoli Innovations invests in early-stage life science, medical, and digital technologies stemming from British universities. The entity is wholly owned by the Perivoli Trust to support educational initiatives in sub-Saharan Africa.

Portfolio

5

companies


Portfolio companies

CE

Cheesecake Energy

Cheesecake Energy develops novel thermal and compressed air energy storage systems for static applications.

Orbit Discovery

Orbit Discovery

Orbit Discovery develops proprietary screening platforms for candidate peptide therapeutics.

L

Lifted

Lifted provides a care management platform that helps families navigate home care.

Oxford Endovascular

Oxford Endovascular

Oxford Endovascular develops origami engineered medical devices to prevent brain haemorrhage.

LT

Legislate Technologies

Legislate Technologies provides a software platform for small businesses and landlords to create and manage contracts.


Recent investments

Seed
£5.6M

The financing round was led by Oxford Sciences Innovation to support the company in expanding its peptide discovery operations.

"Orbit’s team has the right combination of scientific rigor and novel peptide technologies to lead a new generation of drug development, and we look forward to partnering with the team to advance their mission,"
— Nick Dixon-Clegg, Principal
Series A
£4.4M

The London based care technology start up has raised Series A capital from Fuel Ventures and other backers to develop its home care platform and dementia services.

"In the last year, the number of people caring for loved ones has dramatically increased. At Lifted we believe no one should care alone. We are unique in revolutionizing the experience of care for the whole family and for Carers, enabling families to live great lives even in the toughest of times. In 12 months, we have tripled revenue, launched the first App in the world to offer free care advice, and cut Carer churn to half the industry average, all while maintaining exclusively 5 star reviews on Trustpilot."
— Rachael Crook, CEO
Series A
£7.3M

The financing round was led by Vulpes Investment Management with backing from existing investors to fund first in-human data acquisition.

"The current device market for brain aneurysms is valued at well over $1bn and is growing rapidly year-on-year. One of the biggest challenges when it comes to treating neurovascular disease is having devices with high efficacy whilst minimising adverse events. Studies show that often multiple attempts are made to place treatment devices, as they often have challenges of landing accurately, opening and maintaining position. This can lead to adverse events and multiple devices being used. Procedures typically cost over $50,000 to treat a brain aneurysm and a next generation flow diverter overcoming unmet needs, offers the chance for more effective, safer and cost effective treatments as well as allowing many more patients to benefit. We plan to use this funding to bring Oxford Endovascular’s ground-breaking technology to the next stage and gain clinical data from human studies."
— Mike Karim, CEO
Seed
£1.0M

Parkwalk Advisors led the seed round to support product development and UK market expansion.

"This funding will help us accelerate product development and go to market in the UK. Since launching our closed-beta service in June 2020, we have organically doubled our user base every month. We now have more than 800 users, including a handful of early adopters of our paid subscription. Simple legal documents, such as NDAs and tenancy agreements, can be surprisingly frustrating and time-consuming to create, negotiate, and manage, wasting valuable time for landlords and small businesses who don’t have in-house or retained legal support. We saw an opportunity to apply knowledge graph technology to the problem and create a delightful, streamlined contracting experience."
— Charles Brecque, CEO and founder